Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform

Blood

Volumn 117, Issue 19, 2011, Pages 5166-5177

  Slatter, Tania L ^a   Hung, Noelyn ^a   Campbell, Hamish ^b   Rubio, Carina ^b   Mehta, Reena ^b   Renshaw, Prudence ^a   Williams, Gail ^a   Wilson, Michelle ^a   Engelmann, Afra ^b   Jeffs, Aaron ^a   Royds, Janice A ^a   Baird, Margaret A ^a   Braithwaite, Antony W ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 6; ISOPROTEIN; MUTANT PROTEIN; PROTEIN DELTA133P53; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; INFLAMMATION; MOUSE; NEOPLASM; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SURVIVAL TIME;

EID: 79955952990     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-321851     Document Type: Article

References (50)

1. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature. 1992;356(6366):215-221.
2. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast-cancer, sarcomas, and other neoplasms. Science. 1990; 250(4985):1233-1238. (Pubitemid 120031831)
3. Ghosh A, Stewart D, Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol. 2004;24(18): 7987-7997. (Pubitemid 39167449)
4. Flaman JM, Waridel F, Estreicher A, et al. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene. 1996; 12(4):813-818. (Pubitemid 26072268)
5. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005;19(18):2122-2137. (Pubitemid 41330315)
6. Yin YL, Luciani MG, Fahraeus R. p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol. 2002;4(6):462-467. (Pubitemid 34746166)
7. Rohaly G, Chemnitz J, Dehde S, et al. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell. 2005;122(1): 21-32. (Pubitemid 40977937)
8. Virginie M, Staphane P, Mustapha A, et al. Delta160p53 is a novel N-terminal p53 isoform encoded by Delta133p53 transcript. FEBS Lett. 2010;584:4463-4468.
9. Maier B, Gluba W, Bernier B, et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 2004;18(3):306-319. (Pubitemid 38199255)
10. Boldrup L, Bourdon JC, Coates PJ, Sjostrom B, Nylander K. Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer. 2007;43(3):617-623. (Pubitemid 46177591)
11. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res. 2006;12(13):3985-3992. (Pubitemid 44078084)
12. Avery-Kiejda KA, Zhang XD, Adams LJ, et al. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res. 2008;14(6):1659-1668. (Pubitemid 351469449)
13. Fujita K, Mondal AM, Horikawa I, et al. p53 isoforms Delta 133p53 and p53 beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol. 2009;11:1135-1142.
14. Hofstetter G, Berger A, Fiegl H, et al. Alternative splicing of p53 and p73: the novel p53 splice variant p53 delta is an independent prognostic marker in ovarian cancer. Oncogene. 2010; 29(13):1997-2004.
15. Chen J, Ng SM, Chang CQ, et al. p53 isoform Delta 113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev. 2009;23(3):278-290.
16. Aoubala M, Murray-Zmijewski F, Khoury MP, et al. p53 directly transactivates Delta133p53alpha, regulating cell fate outcome in response to DNA damage. Cell Death Differ. 2011;18(2):248-258.
17. Engelmann A, Speidel D, Bornkamm GW, Deppert W, Stocking C. Gadd45[beta] is a prosurvival factor associated with stress-resistant tumors. Oncogene. 2007;27(10):1429-1438.
18. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
19. Dennis G, Sherman BT, Hosack DA, et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(9).
20. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet. 2006; 38(5):500-501.
21. Saldanha AJ. Java Treeview: extensible visualization of microarray data. Bioinformatics. 2004; 20(17):3246-3248.
22. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet. 1995; 10(2):175-180.
23. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387(6630): 299-303. (Pubitemid 27220767)
24. Marcel V, Vijayakumar V, Fernandez-Cuesta L, et al. p53 regulates the transcription of its [Delta]133p53 isoform through specific response elements contained within the Tp53 P2 internal promoter. Oncogene. 2010;29(18):2691-2700.
25. Wei CL, Wu Q, Vega VB, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell. 2006;124(1):207-219. (Pubitemid 43069320)
26. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant nice. Curr Biol. 1994;4(1):1-7.
27. Lang GA, Iwakuma T, Suh YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004;119(6):861-872. (Pubitemid 40017691)
28. Johnson TM, Meade K, Pathak N, Marques MR, Attardi LD. Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc Natl Acad Sci U S A. 2008;105(4):1215-1220. (Pubitemid 351397033)
29. Slatter TL, Ganesan P, Holzhauer C, et al. p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors. Cell Death Differ. 2010;17(3):540-550.
30. MacPherson D, Kim JH, Kim T, et al. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J. 2004;23(18): 3689-3699. (Pubitemid 39336290)
31. Toledo F, Krummel KA, Lee CJ, et al. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell. 2006;9(4):273-285.
32. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 1995;378(6553): 206-208.
33. Luna RMD, Wagner DS, Lozano G. Rescue of early embryonic lethality in Mdm2-deficient mice by deletion of p53. Nature. 1995;378(6553):203-206.
34. Johnson TM, Hammond EM, Giaccia A, Attardi LD. The p53(QS) transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat Genet. 2005;37(2):145-152.
35. Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119(6):847-860. (Pubitemid 40017690)
36. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer. 2007;7(3):165-167.
37. Yin XY, Grove L, Datta NS, Long MW, Prochownik EV. C-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene. 1999;18(5):1177-1184. (Pubitemid 29085990)
38. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412(6844):341-346. (Pubitemid 32691848)
39. Watanuki-Miyauchi R, Kojima Y, Tsurumi H, et al. Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int. 2005;55(6):324-330. (Pubitemid 40910665)
40. Liu L, Zhang M, Zou P. Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leuk Lymphoma. 2007;48(11):2179-2183. (Pubitemid 350091059)
41. Zheng SJ, Lamhamedi-Cherradi SE, Wang P, Xu LY, Chen YH. Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes. 2005;54(5):1423-1428. (Pubitemid 40586673)
42. Komarova EA, Krivokrysenko V, Wang KH, et al. p53 is a suppressor of inflammatory response in mice. FASEB J. 2005;19:1030-1032. (Pubitemid 40827741)
43. Veeranki S, Choubey D. Systemic lupus erythematosus and increased risk to develop B cell malignancies: role of the p200-family proteins. Immunol Lett. 2010;133(1):1-5.
44. Tavana O, Puebla-Osorio N, Sang M, Zhu CM. Absence of p53-dependent apoptosis combined with nonhomologous end-joining deficiency leads to a severe diabetic phenotype in mice. Diabetes. 2010;59(1):135-142.
45. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A. 2002;99(15):10025-10030. (Pubitemid 34831166)
46. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin-6 gene promoter by p53 and the retinoblastoma susceptibility gene-product. Proc Natl Acad Sci U S A. 1991;88(17):7605-7609. (Pubitemid 21915202)
47. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9(13): 4653-4665. (Pubitemid 37323267)
48. Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007;21(14):1714-1719. (Pubitemid 47076470)
49. Ara T, DeClerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46(7):1223-1231.
50. Weichselbaum RR, Ishwaran H, Yoon T, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A. 2008;105(47):18490-18495.